Skip to main content

CombiMatrix Value Stock - Dividend - Research Selection


ISIN: US20009T5011, WKN: A2AD52

Market price date: 30.11.-0001
Market price: 0,00 USD

CombiMatrix Fundamental data and company key figures of the share

Annual reports in USD
Key figures 03-03-2017
Cash flow
Net operating cash flow -3.900.000
Capital Expenditures -157.000
Free cash flow -4.057.000
Balance sheet
Total Equity 6.494.000
Liabilities & Shareholders equity 8.478.000
Income statement
Net income -4.140.000
Eps (diluted) -3,270
Diluted shares outstanding 2.560.000
Net sales/revenue 12.869.000

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization16.000.000,00 USD
Raw Data Source
Stock Split

Description of the company

CombiMatrix Corporation is a molecular diagnostics company. The Company operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. located in Irvine, California. The Company operates as a diagnostics reference laboratory, providing DNA-based clinical diagnostic testing services to physicians, hospitals, clinics and other laboratories in the areas of pre-and postnatal development disorders and hematology/oncology genomics. The Company´s BAC arrays enable the Company to perform aCGH studies to evaluate genomic alterations. The Company´s oligo arrays allow the Company to perform aCGH on a much more refined scale than is possible with BAC technology. During the year ended December 31, 2011, it also owns a 33% interest in Leuchemix, Inc. (Leuchemix), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,